StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Trading Down 13.2 %
Shares of NASDAQ OPGN opened at $1.65 on Thursday. The stock has a fifty day moving average of $1.92 and a 200-day moving average of $2.99. OpGen has a fifty-two week low of $1.61 and a fifty-two week high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.
Institutional Investors Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
See Also
- Five stocks we like better than OpGen
- The 3 Best Blue-Chip Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Secondary Public Offering? What Investors Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.